Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GX-I7 in newly diagnosed glioblastoma
NCT03619239Phase 1Completed
- Sponsor
- Genexine
- Start
- Jun 2018
- Primary completion
- Sep 2020
- Countries
- 1
01
Overview
Phase 1, open-label trial of efineptakin alfa in glioblastoma (GBM) (5 cohorts), sponsored by Genexine. Primary endpoints: Dose-Limiting Toxicity at 2 years and Adverse Events at 2 years. Started Jun 2018; status: completed.
02
Drugs
efineptakin alfa
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03619239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03619239.